<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01598545</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00058097</org_study_id>
    <nct_id>NCT01598545</nct_id>
  </id_info>
  <brief_title>Hydromorphone and C-section</brief_title>
  <official_title>Determination of the ED50 of Intrathecal Hydromorphone for Post-cesarean Section Pain Relief</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the dose of hydromorphone which will relieve the pain of women
      following a cesarean section when delivered directly in the area around the spinal cord
      (i.e., intrathecal injection). The primary objective is to determine the dose of intrathecal
      hydromorphone that results in a pain score of less than 3 out of 10 12 hours after
      intrathecal injection in 50% of women. Secondary objectives include determining the average
      amount of time patients obtain pain relief after injection. Other secondary objectives
      include determining the frequency and severity of side-effects associated with intrathecal
      administration of hydromorphone, including: bradycardia, hypotension, respiratory depression,
      apnea, pruritus, rash, nausea, vomiting, and drowsiness. Thirty women admitted to labor and
      delivery for planned cesarean section desiring will be consented for the study. The starting
      dose of intrathecal hydromorphone will be 6 mcg. The up-and-down sequential allocation method
      of statistical analysis will be used, meaning that each subsequent dose will be dependent
      upon the result obtained from the prior dose - ergo, if the initial subject has pain relief,
      the second subject will receive 4 mcg (2 mcg less), but if the initial subject does not have
      pain relief, the second subject will receive 8 mcg (2 mcg more) of hydromorphone.

      After the intrathecal injection is given, patients will undergo their cesarean section. The
      patient's pain will be assessed at 6, 12, and 18 hours post-injection using a questionnaire.
      The patient's medical record will be reviewed to determine when she first requested
      supplemental pain medication. A pain score of less than three will be a positive result. A
      pain score of three or greater will be a negative result. Blood pressure, heart rate,
      arterial oxygen saturation, 5 and 10 minute APGAR scores, and any side effects will also be
      assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Scores, Visual Analogue Pain Scale</measure>
    <time_frame>12 hours after intrathecal injection</time_frame>
    <description>Continuous Visual Analogue Scale 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Scores, Visual Analogue Pain Scale</measure>
    <time_frame>Baseline</time_frame>
    <description>Continuous Visual Analogue Scale 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores, Visual Analogue Pain Scale</measure>
    <time_frame>6 hours after intrathecal injection</time_frame>
    <description>Continuous Visual Analogue Scale 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores, Visual Analogue Pain Scale</measure>
    <time_frame>18 hours after intrathecal injection</time_frame>
    <description>Continuous Visual Analogue Scale 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores, Visual Analogue Pain Scale</measure>
    <time_frame>24 hours after intrathecal injection</time_frame>
    <description>Continuous Visual Analogue Scale 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Hydromorphone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laboring patients having a cesarean section will receive ED50 of hydromorphone one time intrathecally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone</intervention_name>
    <description>Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.</description>
    <arm_group_label>Hydromorphone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women undergoing cesarean section

        Exclusion Criteria:

          -  Any comorbidities other than obesity, hypertension, fetal anomalies
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grant C Lynde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2012</study_first_submitted>
  <study_first_submitted_qc>May 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2012</study_first_posted>
  <results_first_submitted>December 9, 2014</results_first_submitted>
  <results_first_submitted_qc>December 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 17, 2014</results_first_posted>
  <last_update_submitted>December 9, 2014</last_update_submitted>
  <last_update_submitted_qc>December 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Grant Lynde</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects enrolled from January 2013 to June 2014 at Grady Memorial Hospital.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Hydromorphone</title>
          <description>Laboring patients having a cesarean section will receive ED50 of hydromorphone one time intrathecally
Hydromorphone: Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
ED50 of hydromorphone was 5.6 mcg +/- 1.8 mcg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hydromorphone</title>
          <description>Laboring patients having a cesarean section will receive ED50 of hydromorphone one time intrathecally
Hydromorphone: Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
ED50 of hydromorphone was 5.6 mcg +/- 1.8 mcg.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Scores, Visual Analogue Pain Scale</title>
        <description>Continuous Visual Analogue Scale 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
        <time_frame>12 hours after intrathecal injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>Laboring patients having a cesarean section will receive ED50 of hydromorphone one time intrathecally
Hydromorphone: Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
ED50 of hydromorphone was 5.6 mcg +/- 1.8 mcg.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores, Visual Analogue Pain Scale</title>
          <description>Continuous Visual Analogue Scale 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores, Visual Analogue Pain Scale</title>
        <description>Continuous Visual Analogue Scale 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>Laboring patients having a cesarean section will receive ED50 of hydromorphone one time intrathecally
Hydromorphone: Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
ED50 of hydromorphone was 5.6 mcg +/- 1.8 mcg.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores, Visual Analogue Pain Scale</title>
          <description>Continuous Visual Analogue Scale 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores, Visual Analogue Pain Scale</title>
        <description>Continuous Visual Analogue Scale 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
        <time_frame>6 hours after intrathecal injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>Laboring patients having a cesarean section will receive ED50 of hydromorphone one time intrathecally
Hydromorphone: Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
ED50 of hydromorphone was 5.6 mcg +/- 1.8 mcg.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores, Visual Analogue Pain Scale</title>
          <description>Continuous Visual Analogue Scale 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores, Visual Analogue Pain Scale</title>
        <description>Continuous Visual Analogue Scale 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
        <time_frame>18 hours after intrathecal injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>Laboring patients having a cesarean section will receive ED50 of hydromorphone one time intrathecally
Hydromorphone: Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
ED50 of hydromorphone was 5.6 mcg +/- 1.8 mcg.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores, Visual Analogue Pain Scale</title>
          <description>Continuous Visual Analogue Scale 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores, Visual Analogue Pain Scale</title>
        <description>Continuous Visual Analogue Scale 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
        <time_frame>24 hours after intrathecal injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>Laboring patients having a cesarean section will receive ED50 of hydromorphone one time intrathecally
Hydromorphone: Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
ED50 of hydromorphone was 5.6 mcg +/- 1.8 mcg.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores, Visual Analogue Pain Scale</title>
          <description>Continuous Visual Analogue Scale 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Hydromorphone</title>
          <description>Laboring patients receive ED50 of hydromorphone one time intrathecally
Hydromorphone: Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
ED50 of hydromorphone was 5.6 mcg +/- 1.8 mcg.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Grant Lynde</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-3900</phone>
      <email>glynde@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

